Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome

Phase 3

Completed

• Conditions: Atopic Dermatitis
• Interventions: Drug: 1% OPA-15406; Drug: Placebos

• Registration Number: NCT03908970
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-25
• Study First Submitted: 2019-04-07
• Study First Submitted QC: 2019-04-07
• Study First Posted: 2019-04-09
• Primary Completion: 2019-12-28
• Study Completion: 2019-12-28
• Status Verified: 2021-01
• Results First Submitted: 2021-01-04
• Results First Submitted QC: 2021-01-21
• Last Update Submitted: 2021-01-21
• Results First Posted: 2021-01-25
• Last Update Posted: 2021-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 364

Inclusion Criteria

• Diagnosis of AD based on the Japanese Dermatological Association's criteria
• History of AD for at least 3 years
• Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of body surface area (BSA, excluding scalp) at the screening and baseline examinations
• IGA score of 2 or 3 at the screening and baseline examinations

Exclusion Criteria

• Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1% OPA-15406	1% OPA-15406	Twice daily
Placebo	Placebos	Twice daily

Primary Outcome Measures

Name	Time	Method
Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity	At Week 4	The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score	Baseline, Week 4	The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary.; 0: None; 1. Mild; 2. Moderate; 3. Severe
Change From Baseline in Eczema Area and Severity Index (EASI) Score	Baseline, Week 4	The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs).

Trial Locations

Locations (1)

Kitago Hifuka Clinic; 🇯🇵 Sapporo, Japan